US › Healthcare

Nexalin Technology Inc. (NXL)

US · Healthcare · Medical Devices

$2.35-4.08%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$12,161

Revenue YoY

-82.8%

Net profit

$-2.2M

EPS

$-0.11

EPS estimate

$-0.10

Net margin

-18,412.7%

EPS came in at -0.11 against a street estimate of -0.10 — a miss of 10.0%.

Key statistics

Market cap

$2.8M

Forward P/E

0.0

P/B

2.63

Book value

$2.07

EPS (TTM)

$-14.10

52-week high

$50.70

52-week low

$2.38

50-day MA

$6.95

200-day MA

$12.15

Beta

4.11

Analyst view

Analysts rate Nexalin Technology Inc. a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $15.00.

Shareholding

Insiders

24.58%

Institutions

3.45%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	0.56%
Vanguard Capital Management, LLC	0.51%
Jane Street Group LLC	0.26%
Vanguard Fiduciary Trust Co	0.21%
State Street Corp	0.13%
UBS Group AG	0.11%
Northern Trust Corp	0.10%
Kovack Advisors Inc	0.09%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nexalin Technology Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.